FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378652017> ?p ?o ?g. }

• W4378652017 endingPage "2812" @default.
• W4378652017 startingPage "2799" @default.
• W4378652017 abstract "Nivolumab is an FDA-approved immune checkpoint inhibitor (ICI) for patients with advanced, pre-treated non-small cell lung cancer (NSCLC). However, treatment profiles and patient outcomes often differ in routine clinical practice while the financial impact of approved therapies is largely unknown. In this study, we investigated the efficacy, tolerability, and economic impact of nivolumab in real-world settings (RWS) in Greece.Patients diagnosed with advanced pre-treated NSCLC, receiving nivolumab were recruited from October 2015 until November 2019 across 18 different clinical centers in Greece. Endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Cost analysis was conducted using a third-party public-payer perspective (National Organization for Healthcare Services Provision; EOPYY).A total of 346 patients, median age 66.5 years, were included. With 43.4 months median follow-up, median PFS was 7.8 months and median OS 15.8 months. The 1-year OS rate was 56.5%, 2-year OS 38.8%, and 3-year OS 27.3%. The ORR was 29.5% and DCR 58.7%, with a median response duration of 26.8 months. Patients with objective response were more likely to experience long-term survival (HR=0.14, p<0.001). Only 8.4% of patients experienced grade 3-4 adverse events. The presence of immune-related adverse events was associated with improved OS (HR=0.77, p=0.043). Nivolumab-associated economic burden accounted for €2,214.10 per cycle for each patient, mainly attributed to drug-acquisition costs.This is the first report of real-world efficacy, safety, and economic burden of nivolumab in pre-treated patients with NSCLC in Greece. Indirectly compared to clinical trials, nivolumab was associated with improved efficacy in RWS, further supporting its use in clinical practice and providing insights on clinical prognosticators. The main cost component affecting the nivolumab economic burden was drug-acquisition costs, while toxicity-associated cost was negligible." @default.
• W4378652017 created "2023-05-30" @default.
• W4378652017 creator A5001684767 @default.
• W4378652017 creator A5003935062 @default.
• W4378652017 creator A5005489735 @default.
• W4378652017 creator A5013973547 @default.
• W4378652017 creator A5016114951 @default.
• W4378652017 creator A5017407002 @default.
• W4378652017 creator A5017623388 @default.
• W4378652017 creator A5018787724 @default.
• W4378652017 creator A5021315519 @default.
• W4378652017 creator A5023396290 @default.
• W4378652017 creator A5027224419 @default.
• W4378652017 creator A5030234379 @default.
• W4378652017 creator A5033733633 @default.
• W4378652017 creator A5039349296 @default.
• W4378652017 creator A5041575636 @default.
• W4378652017 creator A5044610238 @default.
• W4378652017 creator A5048322584 @default.
• W4378652017 creator A5050517844 @default.
• W4378652017 creator A5063134810 @default.
• W4378652017 creator A5064636994 @default.
• W4378652017 creator A5070768141 @default.
• W4378652017 creator A5072900712 @default.
• W4378652017 creator A5075544808 @default.
• W4378652017 creator A5084888237 @default.
• W4378652017 creator A5086011046 @default.
• W4378652017 creator A5086594420 @default.
• W4378652017 creator A5089796322 @default.
• W4378652017 creator A5089971238 @default.
• W4378652017 date "2023-05-29" @default.
• W4378652017 modified "2023-09-26" @default.
• W4378652017 title "Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients" @default.
• W4378652017 doi "https://doi.org/10.21873/anticanres.16449" @default.
• W4378652017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37247889" @default.
• W4378652017 hasPublicationYear "2023" @default.
• W4378652017 type Work @default.
• W4378652017 citedByCount "0" @default.
• W4378652017 crossrefType "journal-article" @default.
• W4378652017 hasAuthorship W4378652017A5001684767 @default.
• W4378652017 hasAuthorship W4378652017A5003935062 @default.
• W4378652017 hasAuthorship W4378652017A5005489735 @default.
• W4378652017 hasAuthorship W4378652017A5013973547 @default.
• W4378652017 hasAuthorship W4378652017A5016114951 @default.
• W4378652017 hasAuthorship W4378652017A5017407002 @default.
• W4378652017 hasAuthorship W4378652017A5017623388 @default.
• W4378652017 hasAuthorship W4378652017A5018787724 @default.
• W4378652017 hasAuthorship W4378652017A5021315519 @default.
• W4378652017 hasAuthorship W4378652017A5023396290 @default.
• W4378652017 hasAuthorship W4378652017A5027224419 @default.
• W4378652017 hasAuthorship W4378652017A5030234379 @default.
• W4378652017 hasAuthorship W4378652017A5033733633 @default.
• W4378652017 hasAuthorship W4378652017A5039349296 @default.
• W4378652017 hasAuthorship W4378652017A5041575636 @default.
• W4378652017 hasAuthorship W4378652017A5044610238 @default.
• W4378652017 hasAuthorship W4378652017A5048322584 @default.
• W4378652017 hasAuthorship W4378652017A5050517844 @default.
• W4378652017 hasAuthorship W4378652017A5063134810 @default.
• W4378652017 hasAuthorship W4378652017A5064636994 @default.
• W4378652017 hasAuthorship W4378652017A5070768141 @default.
• W4378652017 hasAuthorship W4378652017A5072900712 @default.
• W4378652017 hasAuthorship W4378652017A5075544808 @default.
• W4378652017 hasAuthorship W4378652017A5084888237 @default.
• W4378652017 hasAuthorship W4378652017A5086011046 @default.
• W4378652017 hasAuthorship W4378652017A5086594420 @default.
• W4378652017 hasAuthorship W4378652017A5089796322 @default.
• W4378652017 hasAuthorship W4378652017A5089971238 @default.
• W4378652017 hasConcept C121608353 @default.
• W4378652017 hasConcept C126322002 @default.
• W4378652017 hasConcept C143998085 @default.
• W4378652017 hasConcept C197934379 @default.
• W4378652017 hasConcept C2776256026 @default.
• W4378652017 hasConcept C2777701055 @default.
• W4378652017 hasConcept C2778375690 @default.
• W4378652017 hasConcept C2780030458 @default.
• W4378652017 hasConcept C71924100 @default.
• W4378652017 hasConceptScore W4378652017C121608353 @default.
• W4378652017 hasConceptScore W4378652017C126322002 @default.
• W4378652017 hasConceptScore W4378652017C143998085 @default.
• W4378652017 hasConceptScore W4378652017C197934379 @default.
• W4378652017 hasConceptScore W4378652017C2776256026 @default.
• W4378652017 hasConceptScore W4378652017C2777701055 @default.
• W4378652017 hasConceptScore W4378652017C2778375690 @default.
• W4378652017 hasConceptScore W4378652017C2780030458 @default.
• W4378652017 hasConceptScore W4378652017C71924100 @default.
• W4378652017 hasIssue "6" @default.
• W4378652017 hasLocation W43786520171 @default.
• W4378652017 hasLocation W43786520172 @default.
• W4378652017 hasOpenAccess W4378652017 @default.
• W4378652017 hasPrimaryLocation W43786520171 @default.
• W4378652017 hasRelatedWork W2770647538 @default.
• W4378652017 hasRelatedWork W2904759734 @default.
• W4378652017 hasRelatedWork W2972926806 @default.
• W4378652017 hasRelatedWork W2984732343 @default.
• W4378652017 hasRelatedWork W3021504039 @default.
• W4378652017 hasRelatedWork W3028884037 @default.
• W4378652017 hasRelatedWork W3029010559 @default.
• W4378652017 hasRelatedWork W3097428643 @default.

• next